Physician profile
Anna E Cattau
NPI 1932532629
$7,251.37
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,665 · 2022: $2,162 · 2023: $2,298 · 2024: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,424.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,423.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,445.02 | 2021-2024 | |
| Novo Nordisk INC | $958.06 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $826.44 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $418.76 | 2021-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $404.96 | 2021-2023 | Spravato, Xarelto |
| Pfizer INC. | $348.21 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $309.76 | 2021-2023 | Breztri, Farxiga, Airsupra |
| Radius Health, INC. | $243.51 | 2023-2024 | Tymlos |
| Abbott Laboratories | $233.37 | 2021-2023 | Freestyle Libre 2, Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $221.32 | 2021-2023 | Xifaxan |
| Amgen INC. | $219.71 | 2021-2023 | Evenity, Prolia |
| Eisai INC. | $195.14 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $178.13 | 2021-2022 | |
| Amarin Pharma, INC. | $151.42 | 2021-2022 | |
| Nevro Corp. | $127.19 | 2021-2023 | Senza |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Cattau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.